The Complement System in Membranous Nephropathy: Pathogenesis and Targeted Therapies

作者
Haoyong Fu,Ying Cong Ryan Shea Tan
出处
期刊: 卷期号:13 (1) 被引量:2
标识
DOI:10.1097/imna-d-24-00059
摘要

Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, marked by the thickening of the glomerular basement membrane due to the deposition of immune complexes. The complement system, a key part of the innate immune response, plays a crucial role in the pathogenesis of MN. Activation of the complement cascade results in glomerular damage, inflammation, and proteinuria. Recent studies have expanded our understanding of the complement system’s involvement in MN and the development of therapies targeting complement to treat the disease.[1] In phospholipase A2 receptor 1 (PLA2R) and thrombospondin Type-1 domain-containing 7A (THSD7A)-associated primary MN, IgG4 is the dominant antibody subclass. Although IgG4 is generally considered unable to activate complement via C1q binding, evidence of classical pathway activation exists in MN. Our previous research detected glomerular C1q deposition in 23% of MN patients, with immunofluorescence revealing C1q on capillary walls.[2] Seifert et al. further demonstrated that at least one of the C1q-binding IgG subclasses (IgG1-3) was present in 100% of MN biopsies examined.[3] These findings, along with strong correlations between IgG1-3 deposition and classical C3 convertase activity, suggest a key role for C1q-binding autoantibodies in classical pathway activation in PLA2R and THSD7A-associated MN. Moreover, Huang et al. found that in kidney pathological stage I of primary MN, glomerular deposits were predominantly IgG1 in most cases; in later stages, IgG4 deposits became dominant. The intensity of IgG4 and C1q staining showed an inverse relationship, suggesting that the classical pathway may be involved in the early stage of primary MN.[4] The lectin pathway, typically involved in recognizing carbohydrate patterns on pathogens, has also been implicated in MN. Although primarily linked to infections and acute inflammation, mannose-binding lectin and other lectin pathway components have been identified in the glomeruli of MN patients. This indicates a potential role for the lectin pathway in MN pathogenesis. Our studies have shown elevated levels of alternative pathway components, such as Bb, in MN, suggesting their involvement in disease progression. The deposition of factor B in MN biopsies further supports alternative pathway activation. Moreover, MN development in a patient with C4 deficiency, in which the classical and lectin pathways were nonfunctional, highlights the alternative pathway’s independent contribution. Continuous low-grade activation of this pathway can sustain inflammatory damage, contributing to MN’s chronic nature. In addition, the relative contribution of each complement pathway likely varies between patients. One pathway may become more active if another is defective or inhibited. Given the central role of complement activation in MN pathogenesis, therapeutic strategies have been developed to target specific components of the complement system. These therapies aim to reduce complement-mediated podocyte injury, inflammation, and proteinuria, ultimately preserving kidney function.[5] Factor B inhibitors (e.g., LNP023) and factor D inhibitors (e.g., BCX9930) block the formation of C3 convertase by inhibiting alternative pathway activation. Although preclinical studies showed a reduction in complement deposition and proteinuria, a phase II trial (NCT04154787) of LNP023 was terminated early after interim analysis, which predicted no superiority of LNP023 versus rituximab in the reduction of urine protein-creatinine ratio at 24 weeks.[6] C3 inhibitors, such as pegcetacoplan and APL2, provide broad inhibition by blocking all three complement pathways. While this approach could be highly effective, it may carry a higher risk of adverse events. A phase II trial (NCT03453619) of APL2 is currently being conducted to assess its efficacy in MN. Lectin pathway inhibitors, targeting components such as mannose-binding lectin-associated serine protease (MASP-2), narsoplimab, hold promise for preventing complement activation in MN. An interim analysis from a phase II trial (NCT02682407) demonstrated significant reductions in proteinuria and stabilization of kidney function. A subsequent phase III trial (NCT03608033) is evaluating its long-term efficacy and safety. More research is needed to determine the exact role of the lectin pathway in MN. Traditional Chinese medicines (TCMs) and their active components can regulate the complement system through a multicomponent and multitarget mechanism, demonstrating unique advantages in the treatment of MN. It can simultaneously intervene in multiple links, including complement activation, clearance of immune complexes, and podocyte protection. Furthermore, compared with traditional complement inhibitors, TCM often exhibits tissue-specific inhibitory effects. For example, Mo Shen Fang could reduce the levels of complement C1q and PLA2R in patients with MN, thereby decreasing proteinuria and improving clinical outcomes.[7] Mahuang Fuzi and Shenzhuo Decoction,[8] Sanqi Qushi Formula,[9] and Jianpi Qushi Heluo Formula have shown therapeutic effects in Passive Heymann Nephritis rats, such as reduced renal injury and glomerular IgG deposition. Tripterygium glycosides reduce autoantibody production (e.g., anti-PLA2R), thereby decreasing C1q activation. Astragaloside (from Astragalus membranaceus) downregulates C1q receptor expression in podocytes, blocking C1q binding and subsequent complement activation.[10] The complement system plays a pivotal role in the pathogenesis of MN through activation of the classical, alternative, and lectin pathways, leading to podocyte damage, proteinuria, and progressive glomerular injury. As our understanding of these mechanisms deepens, therapies targeting specific complement components are emerging as promising treatments. Inhibitors targeting C5, factor B, and C3 offer new approaches for reducing complement-mediated damage and improving patient outcomes. However, further clinical trials are required to confirm their long-term efficacy and safety. Future research should focus on identifying biomarkers to guide the use of these therapies and to better stratify MN patients. Financial support and sponsorship This work was supported by grants from the Beijing Natural Science Foundation (grant number 7242143); Capital’s Funds for Health Improvement and Research (2024-2-4076); National High Level Hospital Clinical Research Funding (Interdisciplinary Research Project of Peking University First Hospital; 2024IR42); the Peking University Clinical Scientist Training Program, supported by “the Fundamental Research Funds for the Central Universities”; the CAMS Innovation Fund for Medical Sciences (2019-I2M-5-046); the Peking University First Hospital Cross-Research Project (No. 2023IR35), and the National Key Research and Development Program of China (2024YFC2511000). Author contributions Fu HR: Writing—Original draft. Tan Y: Writing—Review and Editing. Both authors reviewed and approved the final version of the manuscript. Ethics approval and consent to participate Not applicable. Conflict of interest The authors declare no competing interests. Use of large language models, AI and machine learning tools None declared. Data availability statement No additional data.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研痴发布了新的文献求助10
刚刚
香蕉觅云的应助被霁月采纳,获得10
刚刚
njfu完成签到,获得积分10
刚刚
Haiqing发布了新的文献求助10
刚刚
xiuuu完成签到,获得积分10
1秒前
1秒前
诚心八宝粥完成签到,获得积分10
1秒前
fanfan完成签到 ,获得积分10
1秒前
优秀的不悔完成签到,获得积分10
1秒前
马里奥发布了新的文献求助10
2秒前
建成发布了新的文献求助20
2秒前
lu完成签到,获得积分10
2秒前
LPJ完成签到,获得积分10
2秒前
落雁长歌完成签到,获得积分10
3秒前
3秒前
酷波er的应助被Alvin_Bell采纳,获得10
4秒前
4秒前
菘蓝泽蓼完成签到,获得积分10
4秒前
NAN发布了新的文献求助10
4秒前
黑犬发布了新的文献求助10
4秒前
会飞的鱼发布了新的文献求助10
5秒前
5秒前
5秒前
飞快的代芹完成签到,获得积分10
5秒前
杨德帅发布了新的文献求助10
5秒前
星河发布了新的文献求助10
5秒前
5秒前
5秒前
Keke完成签到,获得积分10
6秒前
xiaxia完成签到,获得积分10
6秒前
安余生完成签到,获得积分10
6秒前
LT完成签到,获得积分10
6秒前
小郭完成签到,获得积分10
6秒前
shen5690完成签到 ,获得积分10
7秒前
8秒前
77完成签到,获得积分20
8秒前
8秒前
Arslanker完成签到,获得积分10
8秒前
Ximian完成签到 ,获得积分10
8秒前
zhoujuan_cip完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185